GlassScriptPhysician profile
Noah S Kornblum
NPI 1053461517
$548.97
in general payments reported to CMS, 2019-2025
18 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.97 · 2020: $40.16 · 2022: $34.88 · 2023: $23.97 · 2024: $125 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $144.76 | 2024-2025 | |
| Kite Pharma, INC. | $100.93 | 2024 | Yescarta |
| Novartis Pharmaceuticals Corporation | $42.39 | 2023-2025 | |
| Medtronic, INC. | $41.06 | 2025 | Osteocool Rf Ablation System |
| Amgen INC. | $39.43 | 2019-2020 | |
| Acrotech Biopharma INC. | $23.27 | 2025 | Beleodaq |
| Gilead Sciences, INC. | $21.59 | 2022 | |
| Pfizer INC. | $20.59 | 2025 | |
| Janssen Biotech, INC. | $19.96 | 2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $19.76 | 2019 | |
| Genentech USA, INC. | $19.32 | 2019 | |
| Dova Pharmaceuticals | $16.06 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.04 | 2019 | |
| Seagen INC. | $13.29 | 2022 | |
| Dendreon Pharmaceuticals LLC | $12.52 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Kornblum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.